Literature DB >> 15385457

Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4.

James M Burns1, Patrick R Flaherty, Payal Nanavati, William P Weidanz.   

Abstract

Strategies to optimize formulations of multisubunit malaria vaccines require a basic knowledge of underlying protective immune mechanisms induced by each vaccine component. In the present study, we evaluated the contribution of antibody-mediated and cell-mediated immune mechanisms to the protection induced by immunization with two blood-stage malaria vaccine candidate antigens, apical membrane antigen 1 (AMA-1) and merozoite surface protein 1 (MSP-1). Immunologically intact or selected immunologic knockout mice were immunized with purified recombinant Plasmodium chabaudi AMA-1 (PcAMA-1) and/or the 42-kDa C-terminal processing fragment of P. chabaudi MSP-1 (MSP-1(42)). The efficacy of immunization in each animal model was measured as protection against blood-stage P. chabaudi malaria. Immunization of B-cell-deficient JH(-/-) mice indicated that PcAMA-1 vaccine-induced immunity is largely antibody dependent. In contrast, JH(-/-) mice immunized with PcMSP-1(42) were partially protected against P. chabaudi malaria, indicating a role for protective antibody-dependent and antibody-independent mechanisms of immunity. The involvement of gammadelta T cells in vaccine-induced PcAMA-1 and/or PcMSP-1(42) protection was minor. Analysis of the isotypic profile of antigen-specific antibodies induced by immunization of immunologically intact mice revealed a dominant IgG1 response. However, neither interleukin-4 and the production of IgG1 antibodies nor gamma interferon and the production of IgG2a/c antibodies were essential for PcAMA-1 and/or PcMSP-1(42) vaccine-induced protection. Therefore, for protective antibody-mediated immunity, vaccine adjuvants and delivery systems for AMA-1- and MSP-1-based vaccines can be selected for their ability to maximize responses irrespective of IgG isotype or any Th1 versus Th2 bias in the CD4(+)-T-cell response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15385457      PMCID: PMC517570          DOI: 10.1128/IAI.72.10.5605-5612.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  52 in total

1.  Immunoglobulin G3 antibodies specific for the 19-kilodalton carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein 1 transfer protection to mice deficient in Fc-gammaRI receptors.

Authors:  P Vukovic; P M Hogarth; N Barnes; D C Kaslow; M F Good
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

Review 2.  Vaccines against asexual stage malaria parasites.

Authors:  Sanjai Kumar; Judith E Epstein; Thomas L Richie
Journal:  Chem Immunol       Date:  2002

Review 3.  Immune responses to liver-stage parasites: implications for vaccine development.

Authors:  Michael R Hollingdale; Urszula Krzych
Journal:  Chem Immunol       Date:  2002

Review 4.  Malaria vaccine trials.

Authors:  Brian Greenwood; Pedro Alonso
Journal:  Chem Immunol       Date:  2002

Review 5.  Malaria and the immune system in humans.

Authors:  Peter Perlmann; Marita Troye-Blomberg
Journal:  Chem Immunol       Date:  2002

6.  IL-12 is required for antibody-mediated protective immunity against blood-stage Plasmodium chabaudi AS malaria infection in mice.

Authors:  Zhong Su; Mary M Stevenson
Journal:  J Immunol       Date:  2002-02-01       Impact factor: 5.422

7.  Specificity of the protective antibody response to apical membrane antigen 1.

Authors:  A N Hodder; P E Crewther; R F Anders
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

8.  Central role of endogenous gamma interferon in protective immunity against blood-stage Plasmodium chabaudi AS infection.

Authors:  Z Su; M M Stevenson
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

Review 9.  Progress and challenges for malaria vaccines.

Authors:  Thomas L Richie; Allan Saul
Journal:  Nature       Date:  2002-02-07       Impact factor: 49.962

10.  Protective immune responses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not by the adjacent 33-kDa region.

Authors:  Niklas Ahlborg; Irene T Ling; Wendy Howard; Anthony A Holder; Eleanor M Riley
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

View more
  15 in total

1.  Splenic gammadelta T cells regulated by CD4+ T cells are required to control chronic Plasmodium chabaudi malaria in the B-cell-deficient mouse.

Authors:  Henri C van der Heyde; Joan M Batchelder; Matyas Sandor; William P Weidanz
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 2.  Depletion and dysfunction of Vγ2Vδ2 T cells in HIV disease: mechanisms, impacts and therapeutic implications.

Authors:  Haishan Li; Suchita Chaudhry; Suchita Chaudry; Bhawna Poonia; Yiming Shao; C David Pauza
Journal:  Cell Mol Immunol       Date:  2012-12-17       Impact factor: 11.530

3.  Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.

Authors:  D Lys Guilbride; Pawel Gawlinski; Patrick D L Guilbride
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

4.  In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized.

Authors:  Kazutoyo Miura; Hong Zhou; Olga V Muratova; Andrew C Orcutt; Birgitte Giersing; Louis H Miller; Carole A Long
Journal:  Infect Immun       Date:  2007-10-08       Impact factor: 3.441

5.  A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits.

Authors:  Edmond J Remarque; Bart W Faber; Clemens H M Kocken; Alan W Thomas
Journal:  Infect Immun       Date:  2008-03-31       Impact factor: 3.441

6.  Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses.

Authors:  Michelle M Lynch; Amy Cernetich-Ott; William P Weidanz; James M Burns
Journal:  Clin Vaccine Immunol       Date:  2008-12-30

7.  Babesia divergens apical membrane antigen 1 and its interaction with the human red blood cell.

Authors:  Estrella Montero; Marilis Rodriguez; Yelena Oksov; Cheryl A Lobo
Journal:  Infect Immun       Date:  2009-08-31       Impact factor: 3.441

8.  Enhanced protection against malaria by a chimeric merozoite surface protein vaccine.

Authors:  Qifang Shi; Michelle M Lynch; Margarita Romero; James M Burns
Journal:  Infect Immun       Date:  2006-12-11       Impact factor: 3.441

9.  Mixed allele malaria vaccines: host protection and within-host selection.

Authors:  Victoria C Barclay; Brian H K Chan; Robin F Anders; Andrew F Read
Journal:  Vaccine       Date:  2008-09-18       Impact factor: 3.641

10.  Temporal stability of naturally acquired immunity to Merozoite Surface Protein-1 in Kenyan adults.

Authors:  Arlene E Dent; Kiprotich Chelimo; Peter O Sumba; Michele D Spring; Brendan S Crabb; Ann M Moormann; Daniel J Tisch; James W Kazura
Journal:  Malar J       Date:  2009-07-16       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.